Castle Biosciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M | $62.6M | $51.9M | $22.8M |
| Cost of Revenue | $71.0M | $60.2M | $45.0M | $32.0M | $15.8M | $9.7M | $7.3M | $5.3M |
| Gross Profit | $273.2M | $271.9M | $174.8M | $105.0M | $78.3M | $53.0M | $44.6M | $17.5M |
| Gross Margin | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% | 84.5% | 85.9% | 76.8% |
| Operating Expenses | ||||||||
| Research & Development | $51.9M | $52.0M | $53.6M | $44.9M | $29.6M | $13.3M | $7.4M | $4.9M |
| SG&A Expense | $229.3M | $200.0M | $180.2M | $143.0M | $86.7M | $48.1M | $29.8M | $16.5M |
| Operating Income | $-42.8M | $8.7M | $-68.0M | $-72.9M | $-40.1M | $-6.5M | $7.3M | $-3.8M |
| Operating Margin | -12.4% | 2.6% | -30.9% | -53.2% | -42.6% | -10.4% | 14.1% | -16.8% |
| Interest Expense | — | — | $11.0K | $17.0K | $1.0K | $2.6M | $4.6M | $2.3M |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $-5.4M | $3.3M | $101.0K | $-1.8M | $-8.7M | $84.0K | $72.0K | $9.0K |
| Net Income | $-24.2M | $18.2M | $-57.5M | $-67.1M | $-31.3M | $-10.3M | $5.3M | $-6.4M |
| Net Margin | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% | -16.4% | 10.2% | -27.9% |
| EPS (Basic) | $-0.83 | $0.66 | $-2.14 | $-2.58 | $-1.24 | $-0.54 | $0.18 | $-0.53 |
| EPS (Diluted) | $-0.83 | $0.62 | $-2.14 | $-2.58 | $-1.24 | $-0.54 | $-0.11 | $-0.53 |
| Shares Outstanding (Basic) | 29.0M | 27.8M | 26.8M | 26.1M | 25.1M | 18.9M | 17.2M | 19.1M |
| Shares Outstanding (Diluted) | 29.0M | 29.3M | 26.8M | 26.1M | 25.1M | 18.9M | 17.3M | 19.1M |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |